Elligo Health Research Partners with Jack Nathan Health
Elligo Health Research, a healthcare-enabling research organization, is helping Jack Nathan Health patients gain access to clinical research as a care option at its Canadian Walmart clinics. Jack Nathan Health operates physician-led medical practices that accommodate clinic appointments, lab services, physiotherapy and chiropractic services, and more.
“We take our commitment to exceptional service and care seriously,” said George Barakat, CEO at Jack Nathan Health. “Partnering with Elligo gives us the opportunity to stay informed of the newest advancements, improve our cutting-edge facilities, and continue to meet our patients’ healthcare challenges.”
This partnership expands Elligo’s Research Ready site network to include healthcare experts and their patients from across. Jack Nathan Health patients who qualify for a research study will be given the opportunity to receive treatment through Elligo’s Goes Direct approach, which connects drug development companies to a diverse pool of patients.
“To date, this is our greatest achievement in our mission to connect research to patients,” said John Potthoff, PhD, CEO of Elligo.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
